Investigating the effect of Syrup based on Naqu Fawakeh on liver enzymes in children with ALL undergoing chemotherapy ,a double blind randomized controlled trial.

Shiraz University of Medical Sciences0 个研究点目标入组 106 人开始时间: 待定最近更新: 2023年11月13日

适应症

试验速览

暂无简介。

•Patients with ALL based on bone marrow aspiration and immunophenotype, aged 5 to 17 years, in the maintenance phase of treatment by methotrexate and 6-mercaptopuril, with liver enzymes level 2 times or more higher than the maximum normal level
•Willingness to participate in the study

•The occurrence of any allergy and intolerance to the drug.
•Diagnosis of liver disease during planning.
•The patient's unwillingness to continue treatment.
•Taking drugs that interfere with the herbs in the composition.
•history of drug sensitivity to the plants in the syrup:Prunus cerasus,Prunus domestica,Alhagi pseudalhagi ,Zizyphus jujube,Cordia myxa ,Tamarindus indica,Prunus armeniaca,Saccharum officinarum
•The patient has diarrhea. (CTCAE questionnaire)[39]
•history of liver disease, viral hepatitis, HIV, diabetes, other malignancies, and chronic intestinal disease.
•Taking drugs with the risk of cholestatic liver damage or damaging liver cells: drugs causing liver cholestasis: amoxicilline and clavulanic acid with consumption of more than 90 mg per kilogram per day, anabolic steroids, chlorpromazin, clopidogrel, erythromycin, irbesartan, mirtazapine, estrogen , terbinafine, drugs that damage liver cells and cause liver cholestasis, amitriptyline, azathioprine: captopril, carbamazepine, clindamycin, co-trimoxazole, cyproheptadine, enalapril, flutamide, nitrofurantoin, phenobarbital, phenytoin, sulphonamide, trazodone, verapamil

发起方